Amgen hold-up gives Mirati a vital lifeline

Six months might not seem like much, but for Mirati every second of it will count. Readout of Amgen’s confirmatory lung cancer trial of Lumakras, yesterday delayed from the first to the second half of this year, buys vital breathing space for Mirati as it scrambles to get its rival adagrasib onto the market.